IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025

IO Biotech, Inc.

2024-Q3 EPS reported -$0.97

Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.
Cash $80.2M as of Sep 30, 2024, down from $143.2M; cash runway into Q4 2025.
Phase 3 trial IO102-IO103 + pembrolizumab in advanced melanoma: PFS primary endpoint expected H1 2025.
Phase 2 SCCHN cohort met primary endpoint; data presented at ESMO and SITC.
Plans BLA submission in 2025 and potential US launch in 2026; IND for IO112 in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.